Apr 19 |
SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
|
Apr 18 |
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
|
Mar 4 |
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
|
Feb 29 |
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
|
Feb 27 |
SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results
|
Feb 27 |
SpringWorks Therapeutics GAAP EPS of -$5.15 misses by $0.23, revenue of $5.45M
|
Feb 27 |
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
|
Feb 22 |
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
|
Feb 16 |
SpringWorks Therapeutics jumps amid takeover speculation
|
Feb 7 |
SpringWorks Therapeutics Inc Insider Sells Company Shares
|